Better oncology drug management could lead to improved outcomes, lower costs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matt Ingram
Vice president of product management, Avalon Healthcare Solutions
Table of Contents

YOU MAY BE INTERESTED IN

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers. 
The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.
Matt Ingram
Vice president of product management, Avalon Healthcare Solutions

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login